Search
Anethole trithione
go.drugbank.com/drugs/DB13853Approvedhepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. … for many of these aforementioned functions at this time and is only used in limited regions around the world.
Danicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization … [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction
Synonyms: (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide, (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamideTechnetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawnA radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy. … Technetium Tc-99m oxidronate, also known as 99mTc-methylene diphosphonate, is a radiopharmaceutical agent.
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawn, resulting in a premature termination of the trial. … In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates
Products: DURAPTAAducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and [solanezumab].
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnIn the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum.
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalIt works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests.
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexExemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalExemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal … It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Products: EXEMESTAN AL 25 MG, EXEMESTAN 1A PHARMA 25MGFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Products: AVAMYS 2A